Overview

Update
Total Equity Funding
$9.81M in 3 Rounds from 3 Investors
Most Recent Funding
$3M Venture on December, 2007
Headquarters:
Montréal, QC
Description:
AngioChem develops new drugs that are capable of crossing the blood-brain barrier to treat brain diseases.
Categories:
Biotechnology
Website:
http://www.angiochem.com

Company Details

Update

AngioChem is a clinical-stage biotechnology discovering and developing new breakthrough drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases. Their EPiC platform solves the key problem for crossing the blood-brain barrier by developing novel drugs that use a receptor-based approach. These novel Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention.

Funding Rounds (3) - $9.81M

Update
DateAmount / RoundValuationLead InvestorInvestors
Dec, 2007$3M / Venture1
Dec, 2005$6M / Venture2
Jan, 2005$807k / Venture1

Board Members and Advisors (1)

Update

Offices/Locations (1)

Update
  • Office

    201 President-Kennedy Ave

    Suite PK-R220, Quebec,

    Montréal, QC H2X 3Y7

    CAN

Past Team (1)

Update

Images (1)

Update

Add Acquisitions

Add Current Team

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos